This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Brown, M. J Search for Related Content Social Bookmarking                         What's this?

Review: Implications from hypertension outcome trials for the management of patients with hypertension and diabetes

Clinical Pharmacology Unit, Level 6, ACCI, Box 110, Addenbrooke's Hospital, Cambridge, CB2 2QQ, UK, m.j.brown{at}cai.cam.ac.uk

The UKPDS highlighted the importance of blood pressure control in patients with type 2 diabetes. In this review I draw on data from the INSIGHT and other recent outcome trials in hypertension which provide clear evidence that it is the achievement of good control of blood pressure, irrespective of the initial choice of drug, that is the major determinant of outcome. The INSIGHT trial provides hard evidence of how resistant to treatment patients with diabetes really are. In this review I offer a theoretical and practical solution in the form of a stepwise algorithm using multiple therapies.

Key Words: hypertension • diabetes • outcome trial • guidelines • calcium channel blocker • diuretic • ACE inhibitor • angiotensin receptor blocker • beta blocker.

References

• Brown MJ, Castaigne A., De Leeuw PW et al. Influence of diabetes and type of hypertension on the response to antihypertensive treatment. Hypertension 2000;35:1038-42.[Abstract/Free Full Text]
• Collins R., MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994;50:272-98.[Abstract/Free Full Text]
• Brown MJ What does STOP-2 tell us about management of hypertension? (Correspondence on STOP-2). Lancet 2000;355:653-4.[Medline] [Order article via Infotrieve]
• Sever PS, Dahlof B., Poulter NR et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens 2001;19:1139-47.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Dahlof B., Devereux RB, Kjeldsen SE et al. The Losartan Intervention For Endpoint Reduction in Hypertension Study. Lancet 2002;359:995-1003.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Neal B., MacMahon S., Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356:1955-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.[Abstract/Free Full Text]
• Brown MJ, Cruickshank JK, Dominiczak AF et al. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003;17:81-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13.[Abstract/Free Full Text]
• Hansson L., Zanchetti A. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ramsay LE, Williams B., Johnston GD et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999; 319:630-5.[Free Full Text]
• Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. Circulation 1999;100:354-60.[Abstract/Free Full Text]
• Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sever P. Abandoning diastole. BMJ 1999;318:1773.[Free Full Text]
• Brown MJ, Palmer CR, Castaigne A. et R al. Morbidity and mortality in patients randomised to double-blind treatment with once-daily calcium channel blockade or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-42.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Cockcroft JR, Brown MJ Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study. Lancet 2002;359:2202; discussion 2203-4.[Medline] [Order article via Infotrieve]
• Kjeldsen SE, Dahlof B., Devereux RB et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002;288:1491-8.[Abstract/Free Full Text]
• Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.[Abstract/Free Full Text]
• Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.[Abstract/Free Full Text]
• Parving HH, Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345: 870-8.[Abstract/Free Full Text]
• Verdecchia P., Schillaci G., Reboldi G., Franklin SS, Porcellati C. Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension. Circulation 2001;103:2579-84.[Abstract/Free Full Text]
• Millar JA, Lever AF Implications of pulse pressure as a predictor of cardiac risk in patients with hypertension. Hypertension 2000;36:907-11.[Abstract/Free Full Text]
• Lind L., Pollare T., Berne C., Lithell H. Long-term metabolic effects of antihypertensive drugs. Am Heart J 1994;128:1177-83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lithell HO, Pollare T., Berne C. Insulin sensitivity in newly detected hypertensive patients: influence of captopril and other antihypertensive agents on insulin sensitivity and related biological parameters. J Cardiovasc Pharmacol 1990;15(suppl 5):S46-S52.
• Pollare T., Lithell H., Selinus I., Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988;31:415-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Colhoun HM, Dong W., Poulter NR Blood pressure screening, management and control in England: results: from the health survey for England 1994. J Hypertens 1998;16:747-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Mancia G., Sega R., Milesi C., Cesana G., Zanchetti A. Blood-pressure control in the hypertensive population. Lancet 1997;349:454-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Geller DS, Farhi A., Pinkerton N. et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000; 289:119-23.[Abstract/Free Full Text]
• Hansson JH, Nelson-WC, Suzuki H. et al. Hypertension caused by a truncated epithelial sodium channel g subunit: genetic heterogeneity of Liddle syndrome. Nature Genet 1995;11:76-82.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Shimkets RA, Warnock DG, Bositis CM et al. Liddle's syndrome: heritable human hypertension caused by mutations in the b-subunit of the epithelial sodium channel. Cell 1994;79:407-14.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Park J., Leong ML, Buse P., Maiyar AC, Firestone GL, Hemmings BA Serum and glucocorticoid-inducible kinase (SGK) is a target of the PI 3-kinase-stimulated signaling pathway. Embo J 1999;18:3024-33.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lang F., Cohen P. Regulation and physiological roles of serum- and glucocorticoid-induced protein kinase isoforms. Sci STKE 2001; 2001(108): RE17.

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 4, 245-251 (2003)
DOI: 10.1177/14746514030030040201


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Brown, M. J Search for Related Content Social Bookmarking                         What's this?